期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

白血病干细胞分子生物学特性及耐药调控机制研究进展 被引量：1

原文传递
导出
摘要 目前人们已公认白血病是一类起源于造血干细胞的克隆性恶性疾病，白血病干细胞（1eukemiastemcell，LSC）与正常造血干细胞（hematopoieticstemcell，HSC）有许多相似之处，其具有自我更新能力和有限的分化潜能，同时又具有其自身独特的特征。LSC本身的分子遗传学改变使其克隆中的白血病细胞增殖与分化失衡，导致细胞停滞在发育早期的不同阶段，虽然LSC存在分化受阻，不能向终末阶段分化，
作者 李红玉 史哲新 沈继春
机构地区 天津中医药大学中西医结合临床专业 天津中医药大学第一附属医院血液科 武警后勤学院附属医院血液科
出处 《中国综合临床》 2015年第3期286-288,共3页 Clinical Medicine of China
关键词 白血病干细胞 分子生物学特性 耐药调控机制 骨髓微环境 细胞周期 研究进展
分类号 R733.71 [医药卫生—肿瘤]
  • 相关文献

参考文献27

  • 1何志旭,尚峰.肿瘤干细胞在白血病发病中的作用及治疗策略[J].实用儿科临床杂志,2009,24(15):1136-1140. 被引量：1
  • 2张丽,梁英民.白血病干细胞的分子调控[J].现代生物医学进展,2009,9(10):1998-2002. 被引量：4
  • 3Chan WI,Huntly BJ. Leukemia stem cells in acute myeloidleukemia [J]. Semin Oncol,2008,35(4) ;326-335.
  • 4Krivtsov AV, Twomey D, Feng Z, et al. Transformation fromcommitted progenitor to leukaemia stem cell initiated by MLL-AF9[J]. Nature,2006,442(7104) :818-822.
  • 5Ravandi F,Estrov Z. Eradication of leukemia stem cells as a newgoal of therapy in leukemia [J]. Clin Cancer Res, 2006,12 ( 2 ):340-344.
  • 6Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverseprognostic factor and therapeutic antibody target on human acutemyeloid leukemia stem cells [ J]. Cell ,2009 ,138 (2) :286-299.
  • 7夏轶姿,朱宝玲,陈慧,姚荣欣.急性髓性白血病患者外周血T淋巴细胞亚群及CD56+细胞的临床意义的分析[J].中国卫生检验杂志,2011,21(1):154-155. 被引量：6
  • 8刘新利,李静,章骏.NF-κB信号与白血病[J].中国细胞生物学学报,2013,35(4):516-525. 被引量：3
  • 9Braun T, Carvalho G, Fabre C, et al. Targeting NF-kappaB inhematologic malignancies [J]. Cell Death Differ, 2006, 13 (5):748-758.
  • 10Guzman ML,Neering SJ,Upchurch D,et al. Nuclear factor-kappaBis constitutively activated in primitive human acute myelogenousleukemia cells [J]. Blood,2001,98(8) :2301-2307.

二级参考文献162

  • 1Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukemia atter transplantation into SCID mice [J]. Nature, 1994,367 (6464):645-648
  • 2Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J]. Nat Med, 1997,3 (7):730-737
  • 3Passegue E, Jamieson Ch, Ailles LE, et al. Normal and leukemic hematopoiesis:are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? [J]. Proc Natl Acad Sci USA, 2003,100 (11): 11842-11849
  • 4Gilliland DG, Jordan CT, Felix CA. The molecular basis of leukemia[J]. Hematol Am Soc Hematol Educ Program, 2004,80-97
  • 5Hope K J, J in L, Dick JE. Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity [J]. Nat Immunol, 2004,5 (7) : 738-743
  • 6Cozzio A, Passegue E, Ayton PM, et al. Similar MLL-associated leukemias arising from self-renewing stem cells and short-lived myeloid progenitors[J]. Genes Dev, 2003, 17 (24):3029-3035
  • 7Krivtsov AV, Twomey D, Feng Z, et al. Transformation from committed progenitor to leukemia stem cell initiated by MLL-AF9[J]. Nature, 2006,442 (7104):818-822
  • 8Ravandi F, Estrov Z. Eradication of leukemia stem cells as a new goal of therapy in leukemia [J]. Clin Cancer Res, 2006,12 (2):340-344
  • 9Gunsilius E. Evidence from a leukemia model for maintenance of vascular endothelium by bone-marrow derived endothelial cells [J]. Adv Exp Med Biol, 2003,522:17-24
  • 10Hong D, Gupta R, Ancliff P, et al. Initiating and cancer-propagating cells in TEL-AML1-associated childhood leukemia.Science, 2008,Jan 18;319(5861):336-339

共引文献17

同被引文献13

  • 1Brothman AH, Persons DL, Shaffer LG. Nomenclature evolution:Changes in the ISCN from the 2005 to the 2009 edition [J].Cytogenet Genome Res, 2009, 127 ( 1 ) : 1-4. doi:' 10. 1159/000279442.
  • 2Bumes E, Rzonsa S, Hutterer M, et al. Adverse event gradingfollowing CTCAE v3. 0 underestimates hypertensive side effects inpatients with glioma treated with Bevacizumab [ J ]. J Neurooncol,2016,127(1) ;191-200. doi; 10. 1007/sll060-015-2031-7.
  • 3Tawfik B,Sliesoraitis S,Lyerly S,et al. Efficacy of the hypomethy-lating agents as frontline,salvage,or consolidation therapy in adultswith acute myeloid leukemia( AML) [ J]. Ann Hematol, 2014,93(1):47-55. doi; 10. 1007/s00277-013-1940-9.
  • 4Song LX,Xu L,Li X,et al. Clinical outcome of treatment with acombined regimen of decitabine and aclacino-mycin/cytarabine forpatients with refractory acute myeloid leukemia [ J]. Ann Hematol,2012,91 (12) : 1879-1886. doi : 10. 1007/s00277-012-1550-y.
  • 5Saunthararajah Y. Key clinical observations after 5-azacytidine anddecitabine treatment of myelodysplastic syndrome's suggest practicalsolutions for better outcomes [ J]. Hematol Am Soc Hematol EducProgram, 2013,2013: 511-521. doi: 10. 1182/asheducation-2013. 1.511.
  • 6Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter,randomized, open-Iabel, phase III trial of decitabine versus patientchoice,with physician advice,of either supportive care or low-dosecytarabine for the treatment of older patients with newly diagnosedacute myeloid leukemia [J]. J Clin Oncol,2012,30(21) :2670-2677. doi: 10. 1200/jc0. 2011. 38. 9429.
  • 7Khan H,Vale C,Bhagat T,et al. Role of DNA methylation in thepathogenesis and treatment of myelodysplastic syndromes [ J].Semin Hematol, 2013,50 ( 1 ) : 16-37. doi: 10. 1053/j. seminhematol. 2013. 01. 001.
  • 8Curti A,Ruggeri L,Parisi S,et al. Larger size of donor alloreactivenk cell repertoire correlates with better response to nk cellimmunotherapy in elderly acute myeloid leukemia patients [J].Clin Cancer Res, 2016, 22 ( 8) : 1914-1921. doi: 10.1158/1078-0432.CCH-15-1604..
  • 9成人急性髓系白血病（非急性早幼粒细胞白血病）中国诊疗指南（2011年版）[J].中华血液学杂志,2011,32(11):804-807. 被引量：179
  • 10王黎,沈志祥.老年急性髓系白血病的特点和治疗策略[J].中华血液学杂志,2013,34(1):76-79. 被引量：38

引证文献1

二级引证文献4

中国综合临床
2015年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部